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Swine-origin pandemic humani n f l u e n z aA ( H 1 N 1 ) 2 0 0 9
rapidly spread around the world since its initial report-
ing on the 25
th of April 2009. To counter the virus, dif-
ferent vaccines were developed. In Belgium, the
Pandemrix vaccine of GSK was used. Part of the Belgian
population was vaccinated, especially those belonging to
risk groups (immunodepressed patients, healthcare
providers, patients with chronic disease, pregnant
women….). In general, vaccine immunogenicity is less
effective in immunodepressed patients than in immuno-
competent patients.
In this study the immunogenicity of the Pandemrix
vaccine was investigated by measuring neutralizing anti-
bodies against A(H1N1)2009 in sera collected from
immunocompetent and immunodepressed patients such
as hemodialysed and renal transplanted patients. In total
32 healthy volunteers (control group), 106 hemodialysed
patients and 112 renal transplanted patients were
recruited. Neutralizing antibodies were measured in sera
collected before (day 0) and 1 month after a single shot
vaccination (day 30) using a seroneutralisation (SN)
assay followed by an immunoenzyme colorimetric reac-
tion to detect influenza A(H1N1)2009 antigen in
infected cells. Geometric mean (GM) titers were deter-
mined at subject level by individual GM of quadrupli-
cates at each time point. Individual and group level titer
ratios (day 30/day 0) with 95% confidence intervals were
determined as well.
The GM titer ratio for the healthy control group was
38 (23-62). For the dialysed patients, the GM titer ratio
was 11 (8-17) and for the group of renal transplanted
patients, the GM titer ratio was 5 (3-6). Differences in
GM titer ratio between the healthy control group and
each group of immunodepressed patients were significant
(p<0,05; T test). Thirty out of 32 healthy participants
(93%) had at least four-fold increases in SN titers
between day 0 and day 30 (seroconversion). Among dia-
lysed participants, 64 out of 106 (60%) had at least four-
fold increases in SN titers between day 0 and day 30, and
among renal transplanted patients, 49 out of 112 partici-
pants (44%) seroconverted between day 0 and day 30.
Differences in seroconversion rates between the healthy
control group and each group of immunodepressed
patients were significant (p<0.05; fisher exact test).
These results suggest that only 60% of dialysed indivi-
duals developed sufficient neutralizing antibody titers
after immunization with this vaccine. As for renal trans-
planted patients, only 44% of the patients developed suf-
ficient neutralizing antibody titers after vaccination.
Alternative vaccines, dosing, adjuvants or schedule stra-
tegies are needed to achieve effective immunization of
these vulnerable populations.
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